Eastman Chemical Company
) announced that it has collaborated with Sinopec Yangzi
Petrochemical Company Limited to build a hydrogenated hydrocarbon
resin plant in Nanjing, China. Both the companies will hold equal
share in the joint venture.
The facility is expected to be operational by the end of 2014 and
will expand Eastman's total capacity for hydrogenated resins by
50%. Once the plant becomes operational, it is expected to produce
50,000 metric tons of Eastman's Adhesives and Plasticizers
segment's Regalite hydrocarbon resins.
Regalite is useful in making packaging and personal hygiene
products, including disposable diapers. The product is quite
versatile and can be used with a variety of polymers.
Eastman Chemical and Sinopec already have a joint venture for
manufacturing Eastman Eastotac resins in Nanjing. The existing
facility will be expanded for the new venture.
In July 2012, Eastman Chemical also took over Missouri-based
chemical company Solutia under a cash and stock deal worth roughly
$4.8 billion (including Solutia debt). The acquisition is expected
to significantly accelerate the company's growth and offer
lucrative opportunities in Asia-Pacific.
Hefty costs associated with the takeover dragged down Eastman's
profit in the second quarter of 2012. The company reported earnings
(from continuing operation) of $1.26 per share in the quarter, down
17% from $1.51 posted a year ago.
Excluding costs related to the acquisition of Solutia Inc. and a
one-time gain, the Tennessee-based chemicals maker earned $1.40 a
share, which outperformed the Zacks Consensus Estimate of $1.34.
Profit (as reported) from continuing operations dropped 19% to $177
DU PONT (EI) DE (DD): Free Stock Analysis
DOW CHEMICAL (DOW): Free Stock Analysis Report
EASTMAN CHEM CO (EMN): Free Stock Analysis
To read this article on Zacks.com click here.
Eastman Chemical continues to expect double-digit earnings growth
in 2012 due to the acquisition of Solutia. The company retained its
adjusted earnings forecast of $5.30 a share for the year, which is
higher than the current Zacks Consensus Estimate of $5.20.
We believe that Eastman Chemical is well positioned to benefit from
the synergies of its Solutia acquisition in second-half 2012. The
company also stands to benefit from business restructuring,
cost-cutting measures and increased capacity additions.
The company, which competes with
The Dow Chemical Company
E. I. du Pont de Nemours and Company
), holds a short-term Zacks #2 Rank, which translates into a
short-term (1 to 3 months) Buy rating. We currently have an
Outperform recommendation on the shares of Eastman Chemicals.